{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-264748","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.394010+00:00","generated_at":"2026-05-17T00:40:39.551669+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aardvark reports ARD-201 preserved lean mass, reduced weight; WE-868 shows >10% weight loss in mCRC patients","bullets":["ARD-201 (ARD-101+sitagliptin) in DIO mice reduced body weight ~19% in 30 days, comparable to high-dose tirzepatide, and preserved lean mass.","In Phase 2a, ARD-101 reduced hunger (CoEQ) and showed weight control signals, well-tolerated with no serious AEs in 14 adults with obesity.","WE-868 (OxPhos modulator) induced >10% average weight loss in mCRC patients over median 10 weeks; in DIO mice, weight loss exceeded semaglutide at 50 mg/kg.","Aardvark plans to start Phase 2 POWER trial (weight regain prevention) for ARD-201 by end 2025; investor webinar scheduled for Nov 5."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-264748","json":"https://secwatch.observer/filing/0001193125-25-264748.json","markdown":"https://secwatch.observer/filing/0001193125-25-264748.md","text":"https://secwatch.observer/filing/0001193125-25-264748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312525264748/0001193125-25-264748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312525264748/ck0001774857-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:40:39.551669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}